DGX Quest Diagnostics Incorporated
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.…
Industry Peers
Diagnostics & ResearchKey Statistics
About Quest Diagnostics (NYSE: DGX)
›
Quest Diagnostics (NYSE: DGX) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 60,000 employees.
The shares were at 259.10 USD on 19 November 2026, up 39.8% over 52 weeks. Its 52-week range is 171.18 USD to 263.19 USD: the price is 1.6% below the high and 51.4% above the low.
At a market capitalisation of 28.50B USD, it trades at 25.8 times trailing earnings and 21.6 times forward earnings. The median trailing P/E of its 18 largest Diagnostics & Research peers is 35.8, a discount of 28% for DGX. It pays a dividend yielding 1.32% (it pays out 25% of its earnings), against a median of 0.73% among the dividend payers in that peer group.
Quest Diagnostics reports return on equity of 13.8%, an operating margin of 14.9% and revenue up 10.0% year over year.
Its debt exceeds its cash by 5.60B USD, a debt-to-equity ratio of 0.92. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 15 analysts cover the stock, with an average rating of Buy; their mean price target of 257.27 USD is 0.7% below the current price. The next earnings report is expected on 9 February 2027.